Ovagen
Evidence: D/EExperimental / Early Research
Evidence Snapshot
Regulatory Context
Ovagen should remain a low-evidence research subject unless stronger exact-compound primary sources are verified.
Research Takeaway
Ovagen is listed in the short-peptide literature as EDL (Glu-Asp-Leu), but its exact tissue-specific attribution required primary-source reconciliation.
See all 5 evidence claims →Quick Summary
Ovagen is listed in the short-peptide gene-regulation literature as the tripeptide Glu-Asp-Leu (EDL). Despite its name, the indexed literature associates it with renal-cell aging and hepatoprotection research, not ovarian or reproductive biology; direct exact-compound evidence remains sparse.
Mechanism & Research Overview
The systematic peptide-gene-regulation review reports that AED and EDL peptides regulated expression of the p53 apoptosis marker in renal cell cultures during senescence.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Ovagen is listed in the short-peptide literature as EDL (Glu-Asp-Leu), but its exact tissue-specific attribution required primary-source reconciliation.
Sources: Peptide Regulation of Gene Expression: A Systematic Review
Supported
The indexed systematic review reports that AED and EDL peptides regulated expression of the p53 apoptosis marker in renal cell cultures during senescence, and describes EDL/Ovagen as associated with regulation of renal-cell function and hepatoprotection -- not ovarian or reproductive biology.
Does not establish
Evidence boundary: This is review-level, class-associated evidence from one research lineage, not a dedicated exact-compound efficacy study.
Sources: Peptide Regulation of Gene Expression: A Systematic Review
Supported
Ovagen appears in peptide-gene-regulation reviews, but review inclusion is not proof of clinical efficacy. Conflicting commercial claims about liver, kidney, gastrointestinal, and reproductive effects must not be merged or repeated without primary evidence.
Sources: Peptide Regulation of Gene Expression: A Systematic Review
Supported
No adequate replicated human efficacy evidence was identified for Ovagen.
Sources: MitoCore Batch 9 human-clinical-evidence literature search audit
Supported
Ovagen should remain a low-evidence research subject unless stronger exact-compound primary sources are verified.
Sources: MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Commercial sources disagree on whether Ovagen should be framed as ovarian/reproductive, renal, hepatic, or gastrointestinal. These descriptions cannot be merged; the primary literature supports renal-cell aging and hepatoprotection research context, not ovarian/reproductive framing.Safety Consideration
Additional direct exact-compound literature was sparse in this search pass -- limited to inclusion in a systematic review, not a dedicated Ovagen study.Safety Consideration
A substantial portion of the Ovagen literature comes from overlapping investigators and institutions within the Khavinson/St. Petersburg bioregulator research program. This concentration limits independent replication and generalizability; repeated publications from the same research lineage should not be interpreted as equivalent to independent multicenter replication.
Research Areas Being Studied
Research areas discussed on this page reflect the Experimental / Early Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check | 2026 | Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Peptide Regulation of Gene Expression: A Systematic Review | 2021 | The review identifies AED as Cartalax and summarizes short-peptide gene-regulatory work. The literature is predominantly mechanistic/preclinical and cannot establish clinical disease-modifying efficacy. | PMCID: PMC8619776. STRUCTURAL BLOCKER: frozen scope also includes Cartalax/AED, Vilon/Lys-Glu, and Livagen/KEDA, none of which have a Peptide document yet; schema's peptideNameFallback field is a single string and cannot hold more than one missing-subject name, so only the one already-existing subject (Vesugen) is linked here. See Stage 2 report. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-17.
Follow research updates for Ovagen
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.